Dr. Rao is a pharmaceutical economist, entrepreneur, and CEO of Epsilon Life Sciences, with deep expertise in biotech company building and strategic value creation.

Dr. Townson is an executive bringing three decades of oncology and cell therapy leadership from Bayer, Novartis, and Pfizer.

Dr. Lollar is a hematologist and Hemophilia of Georgia Professor of Pediatrics at Emory University. He also invented Obizur, a commercialized Factor VIII recombinant.

Ms. Grove has 20+ years of finance & accounting experience at Navigant Consulting, Inc., an NYSE-listed public company, and at Epsilon Life Sciences.

Dr. Doering is a Professor of Pediatrics at Emory Medical School, leading drug discovery programs on gene and protein engineering.​

Dr. Abshire is a hematologist-oncologist, recognized for pioneering research in bleeding disorders and childhood Leukemia.

Ms. Nearing has 20+ years of biotech experience in investment banking, venture capital, and senior industry roles at Amgen & IBM Healthcare, driving strategic partnerships and commercial growth.

Mr. Swaney has 25+ years of GMP experience manufacturing 100+ viral vectors and cellular products, including pioneering gene therapies such as CARVYKTI®.

Dr. Ness is an expert in transfusion medicine, hematology, and oncology at Johns Hopkins University, with decades of clinical and research leadership in blood disorders and cellular therapies.

Dr. Key is a hematologist, a Professor of Medicine at University of North Carolina at Chapel Hill (UNC), and Director of the UNC Blood Research Center.

Dr. Ear is an Associate Professor at the Winship Cancer Institute of Emory University, specializing in neuroendocrine tumors and cancer metabolism.

Dr. Halperin is a medical oncologist at Emory University specializing in neuroendocrine tumors and gastro-intestinal cancers, with extensive clinical trial experience.

Jim Baker is a managing partner and co-head for Kayne Anderson’s energy infrastructure strategies, responsible for overseeing the group’s investment strategies. Baker serves as chairman of the board, president and CEO of KYN.